Paper Details

  1. Home
  2. Paper Details

Anagrelide treatment in myeloproliferative disorders.

Author: BirgegardGunnar

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Anagrelide is a drug used to lower platelet levels in patients with essential thrombocythemia. It is effective in 70-80% of patients and most reach their treatment goal within weeks. Common side effects include palpitation, headache, diarrhea, and edema. 30-50% of patients discontinue treatment due to side effects. Anagrelide is registered in Europe as a second-line therapy but often used as a first-line therapy in the US, especially in younger patients.
Paper Details　
Original Abstract of the Article :
Platelet-lowering therapy in myeloproliferative disorders includes cytostatic drugs, mainly hydroxyurea, interferon alpha, and anagrelide. Anagrelide is the latest addition to the therapeutic arsenal, and the basis for its use is reviewed. The platelet-lowering efficacy is 70 to 80% in essential thr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1055/s-2006-939437

データ提供：米国国立医学図書館（NLM）

Anagrelide: A New Hope for Myeloproliferative Disorders

This study explores the use of anagrelide, a drug that lowers platelet levels, in the treatment of myeloproliferative disorders, a group of conditions characterized by the overproduction of blood cells. It's like discovering a new oasis in the desert of hematological diseases, offering a potential solution for these often debilitating conditions. The researchers examine the effectiveness of anagrelide in controlling platelet levels and discuss its potential benefits and risks.

Anagrelide: A Promising Treatment for Myeloproliferative Disorders

The study found that anagrelide is effective in reducing platelet levels in patients with essential thrombocythemia, a common myeloproliferative disorder. This research is like a beacon of hope in the desert of hematological diseases, offering a new avenue for treatment. While anagrelide can be effective, it's important to be aware of its potential side effects and the need for careful monitoring during treatment.

Managing Myeloproliferative Disorders

This research emphasizes the importance of having effective treatment options for myeloproliferative disorders, conditions that can significantly impact a person's health and quality of life. It's like providing a lifeline in the desert of disease, offering support and hope for those facing these challenges. The study highlights the role of anagrelide as a potential treatment, offering a new avenue for managing these complex disorders.

Dr.Camel's Conclusion

This study highlights the potential of anagrelide as a treatment option for myeloproliferative disorders, offering a new ray of hope in the desert of these challenging conditions. It's a reminder that even in the most difficult situations, there are often new discoveries and opportunities for improvement. The researchers' insights into the use of anagrelide provide valuable information that can guide clinical decision-making, leading to better outcomes for patients facing these disorders.

Date :
  1. Date Completed 2006-07-25
  2. Date Revised 2016-11-28
Further Info :

Pubmed ID

16673280

DOI: Digital Object Identifier

10.1055/s-2006-939437

Related Literature

Article Analysis
・Side Effects of anagrelide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.